James Burns, a veteran biopharmaceutical executive, has been appointed chief executive of Casebia Therapeutics LLP, a new joint venture gene editing company focused on developing medicines for blood disorders, blindness and heart disease. Cambridge, Massachusetts-based Casebia is owned by Bayer of Germany and Crispr Therapeutics of Switzerland. Dr Burns joins the company from Sanofi SA where he headed that company’s North American research and development activities. He was previously.an executive at Genzyme, which was acquired by Sanofi in 2011.
Dr Burns has a doctorate in bioengineering from the University of Illinois-Chicago and is a member of the US National Academy of Engineering.
Casebia Therapeutics announced the appointment on 1 November 2016
Copyright 2016 Evernow Publishing Ltd